Difference between revisions of "Team:SYSU-MEDICINE"
| Line 16: | Line 16: | ||
<p> | <p> | ||
Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapy to treat several diseases. Up to now, MSCs are used in over 600 ongoing clinical trials (June, 2016) like treating IBD, diabetes, encephalitis, etc. MSCs in current clinical use are isolated from bone marrow, adipose tissue and the umbilical cord. Different from the embryonic stem cells, MSCs have been shown to be highly immunosuppressive. In many studies, MSCs were found to suppress adaptive immune system as well as inherent immune system in multiple inflammatory diseases, which make MSCs a promising tool in treating inflammatory disease. | Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapy to treat several diseases. Up to now, MSCs are used in over 600 ongoing clinical trials (June, 2016) like treating IBD, diabetes, encephalitis, etc. MSCs in current clinical use are isolated from bone marrow, adipose tissue and the umbilical cord. Different from the embryonic stem cells, MSCs have been shown to be highly immunosuppressive. In many studies, MSCs were found to suppress adaptive immune system as well as inherent immune system in multiple inflammatory diseases, which make MSCs a promising tool in treating inflammatory disease. | ||
| + | <br> | ||
<br> | <br> | ||
Despite significant advantages, clinical trials of MSCs have produced mixed results which may significantly impede the advancement of MSC-based therapies. One of the most important reasons is for the inefficient homing ability of MSC that only a few MSC can indeed arrived the inflamed tissue after systematic administration and exert their immunomodulatory function. | Despite significant advantages, clinical trials of MSCs have produced mixed results which may significantly impede the advancement of MSC-based therapies. One of the most important reasons is for the inefficient homing ability of MSC that only a few MSC can indeed arrived the inflamed tissue after systematic administration and exert their immunomodulatory function. | ||
| + | <br> | ||
<br> | <br> | ||
This summer, next generation of MSCs are coming. We intend to construct a circuit of three plasmids that will be able to reinforce the locating function of MSCs. Previous studies have demonstrated that immune cells depend on chemokine receptors to accomplish directional moving. In our project, we are going to empower MSCs with chemokine receptors in order to ensure its effective homing. At the same time, with the purpose of locating in vivo MSC and assuring their arrival at the inflamed tissue, we will introduce several kinds of positioning system into our system and detect them by various methods. | This summer, next generation of MSCs are coming. We intend to construct a circuit of three plasmids that will be able to reinforce the locating function of MSCs. Previous studies have demonstrated that immune cells depend on chemokine receptors to accomplish directional moving. In our project, we are going to empower MSCs with chemokine receptors in order to ensure its effective homing. At the same time, with the purpose of locating in vivo MSC and assuring their arrival at the inflamed tissue, we will introduce several kinds of positioning system into our system and detect them by various methods. | ||
| + | <br> | ||
<br> | <br> | ||
</p> | </p> | ||
Revision as of 16:03, 30 June 2016
Brief Introduction
The team SYSU-MEDICINE
Current Design
Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapy to treat several diseases. Up to now, MSCs are used in over 600 ongoing clinical trials (June, 2016) like treating IBD, diabetes, encephalitis, etc. MSCs in current clinical use are isolated from bone marrow, adipose tissue and the umbilical cord. Different from the embryonic stem cells, MSCs have been shown to be highly immunosuppressive. In many studies, MSCs were found to suppress adaptive immune system as well as inherent immune system in multiple inflammatory diseases, which make MSCs a promising tool in treating inflammatory disease.
Despite significant advantages, clinical trials of MSCs have produced mixed results which may significantly impede the advancement of MSC-based therapies. One of the most important reasons is for the inefficient homing ability of MSC that only a few MSC can indeed arrived the inflamed tissue after systematic administration and exert their immunomodulatory function.
This summer, next generation of MSCs are coming. We intend to construct a circuit of three plasmids that will be able to reinforce the locating function of MSCs. Previous studies have demonstrated that immune cells depend on chemokine receptors to accomplish directional moving. In our project, we are going to empower MSCs with chemokine receptors in order to ensure its effective homing. At the same time, with the purpose of locating in vivo MSC and assuring their arrival at the inflamed tissue, we will introduce several kinds of positioning system into our system and detect them by various methods.
Before you start:
Please read the following pages:
Styling your wiki
You may style this page as you like or you can simply leave the style as it is. You can easily keep the styling and edit the content of these default wiki pages with your project information and completely fulfill the requirement to document your project.
While you may not win Best Wiki with this styling, your team is still eligible for all other awards. This default wiki meets the requirements, it improves navigability and ease of use for visitors, and you should not feel it is necessary to style beyond what has been provided.
Wiki template information
We have created these wiki template pages to help you get started and to help you think about how your team will be evaluated. You can find a list of all the pages tied to awards here at the Pages for awards link. You must edit these pages to be evaluated for medals and awards, but ultimately the design, layout, style and all other elements of your team wiki is up to you!
Editing your wiki
On this page you can document your project, introduce your team members, document your progress and share your iGEM experience with the rest of the world!
Tips
This wiki will be your team’s first interaction with the rest of the world, so here are a few tips to help you get started:
- State your accomplishments! Tell people what you have achieved from the start.
- Be clear about what you are doing and how you plan to do this.
- You have a global audience! Consider the different backgrounds that your users come from.
- Make sure information is easy to find; nothing should be more than 3 clicks away.
- Avoid using very small fonts and low contrast colors; information should be easy to read.
- Start documenting your project as early as possible; don’t leave anything to the last minute before the Wiki Freeze. For a complete list of deadlines visit the iGEM 2016 calendar
- Have lots of fun!
Inspiration
You can also view other team wikis for inspiration! Here are some examples:
Uploading pictures and files
You can upload your pictures and files to the iGEM 2016 server. Remember to keep all your pictures and files within your team's namespace or at least include your team's name in the file name.
When you upload, set the "Destination Filename" to Team:YourOfficialTeamName/NameOfFile.jpg. (If you don't do this, someone else might upload a different file with the same "Destination Filename", and your file would be erased!)
